Dendritic cells (DC) are immune cells that provide cancer markers (cancer antigens) to T lymphocytes, which directly attack cancer cells in the body, and give them instructions to attack. When cancer cell proteins are taken up by dendritic cells, they are degraded intracellularly and stored in the dendritic cells as information (antigens) about the patient’s cancer. The dendritic cells then produce the stored antigen as a marker on the surface.

By returning the antigen to the patient’s body, it is possible to efficiently induce T lymphocytes (cytotoxic T lymphocytes: CTL), which rely on the “markers” and attack only cancer cells intensively.

Our new technology has been added to this therapy to increase its efficiency.

Compared to conventional antigen-presenting cells that only take up antigens, the addition of the new adjuvant technology makes it possible to predominantly activate cancer antigen-specific Th1 cells (CD4+ cells). As a result, not only can CTLs be strongly induced, but it is also expected to have the effect of simultaneously releasing part of the immunosuppression created by cancer cells.